A more immunogenic BCG also has implications for cancer as increasing host production of multiple cytokines with anti-tumor activity (i.e., IL-12p40, RANTES, IL21, and IL-2) has the potential to overcome some of the limitations of current BCG vaccines as cancer immunotherapy [76], [77]. The gene discussed is IL2; the disease is cancer.